Antisense oligonucleotides for therapeutic intervention

Stephen L. Eck, Gary J. Nabel

Research output: Contribution to journalArticle

Abstract

Advances have been made in defining the best target sequences for use in antisense oligonucleotide technology, and new chemical derivatives of oligonucleotides are being investigated. Although the potential use of antisense oligonucleotide agents in the treatment of neoplastic, viral and parasitic diseases continues to be explored, they are not yet suitable for administration to humans for reasons that are discussed.

Original languageEnglish (US)
Pages (from-to)897-904
Number of pages8
JournalCurrent Opinion in Biotechnology
Volume2
Issue number6
DOIs
StatePublished - 1991
Externally publishedYes

Fingerprint

Antisense Oligonucleotides
Oligonucleotides
Parasitic Diseases
Virus Diseases
Technology
Derivatives
Therapeutics

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Biomedical Engineering

Cite this

Antisense oligonucleotides for therapeutic intervention. / Eck, Stephen L.; Nabel, Gary J.

In: Current Opinion in Biotechnology, Vol. 2, No. 6, 1991, p. 897-904.

Research output: Contribution to journalArticle

Eck, Stephen L. ; Nabel, Gary J. / Antisense oligonucleotides for therapeutic intervention. In: Current Opinion in Biotechnology. 1991 ; Vol. 2, No. 6. pp. 897-904.
@article{2d9e281028aa4650bd421bf0a01fb666,
title = "Antisense oligonucleotides for therapeutic intervention",
abstract = "Advances have been made in defining the best target sequences for use in antisense oligonucleotide technology, and new chemical derivatives of oligonucleotides are being investigated. Although the potential use of antisense oligonucleotide agents in the treatment of neoplastic, viral and parasitic diseases continues to be explored, they are not yet suitable for administration to humans for reasons that are discussed.",
author = "Eck, {Stephen L.} and Nabel, {Gary J.}",
year = "1991",
doi = "10.1016/S0958-1669(05)80128-4",
language = "English (US)",
volume = "2",
pages = "897--904",
journal = "Current Opinion in Biotechnology",
issn = "0958-1669",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - Antisense oligonucleotides for therapeutic intervention

AU - Eck, Stephen L.

AU - Nabel, Gary J.

PY - 1991

Y1 - 1991

N2 - Advances have been made in defining the best target sequences for use in antisense oligonucleotide technology, and new chemical derivatives of oligonucleotides are being investigated. Although the potential use of antisense oligonucleotide agents in the treatment of neoplastic, viral and parasitic diseases continues to be explored, they are not yet suitable for administration to humans for reasons that are discussed.

AB - Advances have been made in defining the best target sequences for use in antisense oligonucleotide technology, and new chemical derivatives of oligonucleotides are being investigated. Although the potential use of antisense oligonucleotide agents in the treatment of neoplastic, viral and parasitic diseases continues to be explored, they are not yet suitable for administration to humans for reasons that are discussed.

UR - http://www.scopus.com/inward/record.url?scp=0026290751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026290751&partnerID=8YFLogxK

U2 - 10.1016/S0958-1669(05)80128-4

DO - 10.1016/S0958-1669(05)80128-4

M3 - Article

C2 - 1367966

AN - SCOPUS:0026290751

VL - 2

SP - 897

EP - 904

JO - Current Opinion in Biotechnology

JF - Current Opinion in Biotechnology

SN - 0958-1669

IS - 6

ER -